» Articles » PMID: 33815055

Involvement of Astrocytes and MicroRNA Dysregulation in Neurodegenerative Diseases: From Pathogenesis to Therapeutic Potential

Overview
Specialty Molecular Biology
Date 2021 Apr 5
PMID 33815055
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Astrocytes are the most widely distributed and abundant glial cells in the central nervous system (CNS). Neurodegenerative diseases (NDDs) are a class of diseases with a slow onset, progressive progression, and poor prognosis. Common clinical NDDs include Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD). Although these diseases have different etiologies, they are all associated with neuronal loss and pathological dysfunction. Accumulating evidence indicates that neurotransmitters, neurotrophic factors, and toxic metabolites that are produced and released by activated astrocytes affect and regulate the function of neurons at the receptor, ion channel, antigen transfer, and gene transcription levels in the pathogenesis of NDDs. MicroRNAs (miRNAs) are a group of small non-coding RNAs that play a wide range of biological roles by regulating the transcription and post-transcriptional translation of target mRNAs to induce target gene expression and silencing. Recent studies have shown that miRNAs participate in the pathogenesis of NDDs by regulating astrocyte function through different mechanisms and may be potential targets for the treatment of NDDs. Here, we review studies of the role of astrocytes in the pathogenesis of NDDs and discuss possible mechanisms of miRNAs in the regulation of astrocyte function, suggesting that miRNAs may be targeted as a novel approach for the treatment of NDDs.

Citing Articles

Dysregulation of a Heme Oxygenase-Synuclein Axis in Parkinson Disease.

Cressatti M, Schipper H NeuroSci. 2024; 3(2):284-299.

PMID: 39483365 PMC: 11523740. DOI: 10.3390/neurosci3020020.


Cytotoxic Impact of Naringenin-Loaded Solid Lipid Nanoparticles on RIN5F Pancreatic β Cells Autophagy Blockage.

Pour P, Nouri Z, Ghasemi D, Sajadimajd S, Farzaei M Recent Adv Drug Deliv Formul. 2024; 18(4):304-314.

PMID: 39356101 DOI: 10.2174/0126673878297658240804192222.


Octadecaneuropeptide, ODN, Promotes Cell Survival against 6-OHDA-Induced Oxidative Stress and Apoptosis by Modulating the Expression of miR-34b, miR-29a, and miR-21in Cultured Astrocytes.

Bourzam A, Hamdi Y, Bahdoudi S, Duraisamy K, El Mehdi M, Basille-Dugay M Cells. 2024; 13(14.

PMID: 39056770 PMC: 11487398. DOI: 10.3390/cells13141188.


Neuronal dysfunction and gene modulation by non-coding RNA in Parkinson's disease and synucleinopathies.

Meccariello R, Carlo Bellenchi G, Pulcrano S, DAddario S, Tafuri D, Mercuri N Front Cell Neurosci. 2024; 17:1328269.

PMID: 38249528 PMC: 10796818. DOI: 10.3389/fncel.2023.1328269.


Emerging roles of astrocytes in blood-brain barrier disruption upon amyloid-beta insults in Alzheimer's disease.

Yue Q, Man Hoi M Neural Regen Res. 2023; 18(9):1890-1902.

PMID: 36926705 PMC: 10233760. DOI: 10.4103/1673-5374.367832.


References
1.
van Scheppingen J, Mills J, Zimmer T, Broekaart D, Iori V, Bongaarts A . miR147b: A novel key regulator of interleukin 1 beta-mediated inflammation in human astrocytes. Glia. 2018; 66(5):1082-1097. DOI: 10.1002/glia.23302. View

2.
Izadpanah M, Seddigh A, Barough S, Shahzadeh Fazeli S, Ai J . Potential of Extracellular Vesicles in Neurodegenerative Diseases: Diagnostic and Therapeutic Indications. J Mol Neurosci. 2018; 66(2):172-179. DOI: 10.1007/s12031-018-1135-x. View

3.
Stenvang J, Kauppinen S . MicroRNAs as targets for antisense-based therapeutics. Expert Opin Biol Ther. 2007; 8(1):59-81. DOI: 10.1517/14712598.8.1.59. View

4.
Sofroniew M, Vinters H . Astrocytes: biology and pathology. Acta Neuropathol. 2009; 119(1):7-35. PMC: 2799634. DOI: 10.1007/s00401-009-0619-8. View

5.
Heemels M . Neurodegenerative diseases. Nature. 2016; 539(7628):179. DOI: 10.1038/539179a. View